Trial reportJournal of clinical hypertension (Greenwich, Conn.)2019
Effect of suvorexant on nighttime blood pressure in hypertensive patients with insomnia: The SUPER-1 study.
Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Effect of suvorexant on nighttime blood pressure in hypertensive patients with insomnia: The SUPER-1 study.Journal of clinical hypertension (Greenwich, Conn.) · 2019Trial
- Insomnia and Cardiovascular Disease: Untangling a Complex Relationship.Journal of sleep research · 2026Review
- Early life stress and hormonal status influence orexin-1 receptor expression in structures regulating cardiorespiratory responses to COExperimental physiology · 2025Article
- A review of symptom, pathogenesis and treatment characteristics of the elderly with chronic insomnia.Medicine · 2025Review
- Pharmacological and psychological approaches to insomnia treatment in cardiac patients: a narrative literature review.Frontiers in psychiatry · 2025Review
- Clinical studies on pharmacological treatment of hypertension in Japan.Journal of human hypertension · 2024Review
- Hypertension facilitates age-related diseases. ~ Is hypertension associated with a wide variety of diseases?~.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Review
- Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations.Nature and science of sleep · 2023Review
- Orexin, Sleep, Sympathetic Neural Activity, and Cardiovascular Function.Hypertension (Dallas, Tex. : 1979) · 2022Review
- Treating sleep disorders to improve blood pressure control and cardiovascular prevention: a dream come true?-a narrative review.Journal of thoracic disease · 2020Review
- Type 5 phosphodiesterase (PDE5) and the vascular tree: From embryogenesis to aging and disease.Mechanisms of ageing and development · 2020Review
- Key Points of the 2019 Japanese Society of Hypertension Guidelines for the Management of Hypertension.Korean circulation journal · 2019Review
- Insomnia and hypertension: A misty landscape.Journal of clinical hypertension (Greenwich, Conn.) · 2019Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Orexins are neuropeptides that play a role in maintaining wakefulness and contribute to central regulation of cardiovascular function. This first multicenter, randomized, double-blind study investigated the effects of suvorexant, a reversible dual orexin receptor antagonist, on nighttime blood pressure (BP) in patients with insomnia and hypertension. After a 4-week run-in period, adult outpatients (n = 82) with treated hypertension (clinic SBP <160 mm Hg) and insomnia were treated with suvorexant 20 mg/d or placebo before bedtime for 2 weeks. Twenty-four-hour ambulatory BP monitoring was performed at baseline and the end of treatment, and home BP measurements (morning and evening) were taken daily. Nighttime systolic BP (SBP), the primary endpoint, decreased slightly from baseline to week 2 in both the suvorexant and placebo groups (-4.4 vs -1.8 mm Hg; P = 0.494). Clinic, 24-hour, daytime and morning SBP (ambulatory blood pressure monitoring) also decreased slightly and similarly from baseline in both groups. In this study, suvorexant had no overall effect on BP in patients with insomnia and treated hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.